Logo image of GSD.CA

DEVONIAN HEALTH GROUP INC (GSD.CA) Stock Fundamental Analysis

TSX-V:GSD - TSX Venture Exchange - CA2518348008 - Common Stock - Currency: CAD

0.15  0 (0%)

Fundamental Rating

3

Taking everything into account, GSD scores 3 out of 10 in our fundamental rating. GSD was compared to 35 industry peers in the Pharmaceuticals industry. GSD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GSD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year GSD has reported negative net income.
In the past year GSD had a positive cash flow from operations.
In the past 5 years GSD always reported negative net income.
GSD had negative operating cash flow in 4 of the past 5 years.
GSD.CA Yearly Net Income VS EBIT VS OCF VS FCFGSD.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M

1.2 Ratios

GSD has a Return On Assets of -22.47%. This is in the lower half of the industry: GSD underperforms 68.57% of its industry peers.
GSD's Return On Equity of -58.41% is on the low side compared to the rest of the industry. GSD is outperformed by 65.71% of its industry peers.
The Return On Invested Capital of GSD (8.78%) is better than 91.43% of its industry peers.
Industry RankSector Rank
ROA -22.47%
ROE -58.41%
ROIC 8.78%
ROA(3y)-15.3%
ROA(5y)-19%
ROE(3y)-22.22%
ROE(5y)-31.55%
ROIC(3y)N/A
ROIC(5y)N/A
GSD.CA Yearly ROA, ROE, ROICGSD.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

GSD's Operating Margin of 3.30% is fine compared to the rest of the industry. GSD outperforms 74.29% of its industry peers.
GSD has a better Gross Margin (37.10%) than 62.86% of its industry peers.
In the last couple of years the Gross Margin of GSD has declined.
Industry RankSector Rank
OM 3.3%
PM (TTM) N/A
GM 37.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-5.88%
GSD.CA Yearly Profit, Operating, Gross MarginsGSD.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), GSD is creating some value.
GSD has more shares outstanding than it did 1 year ago.
GSD has more shares outstanding than it did 5 years ago.
The debt/assets ratio for GSD has been reduced compared to a year ago.
GSD.CA Yearly Shares OutstandingGSD.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
GSD.CA Yearly Total Debt VS Total AssetsGSD.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of 0.83, we must say that GSD is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of GSD (0.83) is better than 74.29% of its industry peers.
GSD has a debt to FCF ratio of 0.02. This is a very positive value and a sign of high solvency as it would only need 0.02 years to pay back of all of its debts.
GSD's Debt to FCF ratio of 0.02 is amongst the best of the industry. GSD outperforms 100.00% of its industry peers.
GSD has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
GSD has a Debt to Equity ratio of 0.01. This is in the better half of the industry: GSD outperforms 80.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.02
Altman-Z 0.83
ROIC/WACC1.04
WACC8.47%
GSD.CA Yearly LT Debt VS Equity VS FCFGSD.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M

2.3 Liquidity

GSD has a Current Ratio of 1.12. This is a normal value and indicates that GSD is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.12, GSD is not doing good in the industry: 68.57% of the companies in the same industry are doing better.
A Quick Ratio of 1.12 indicates that GSD should not have too much problems paying its short term obligations.
GSD has a Quick ratio (1.12) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 1.12
GSD.CA Yearly Current Assets VS Current LiabilitesGSD.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

3

3. Growth

3.1 Past

GSD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -60.37%.
GSD shows a strong growth in Revenue. In the last year, the Revenue has grown by 237.82%.
GSD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 26.59% yearly.
EPS 1Y (TTM)-60.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1146.15%
Revenue 1Y (TTM)237.82%
Revenue growth 3Y135.68%
Revenue growth 5Y26.59%
Sales Q2Q%43.66%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GSD.CA Yearly Revenue VS EstimatesGSD.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GSD. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GSD.CA Price Earnings VS Forward Price EarningsGSD.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

GSD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GSD is cheaper than 82.86% of the companies in the same industry.
GSD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. GSD is cheaper than 97.14% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.64
EV/EBITDA 7.38
GSD.CA Per share dataGSD.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15 0.2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GSD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DEVONIAN HEALTH GROUP INC

TSX-V:GSD (7/28/2025, 7:00:00 PM)

0.15

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)06-26 2025-06-26
Earnings (Next)11-27 2025-11-27
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners14%
Ins Owner ChangeN/A
Market Cap22.23M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.67
P/FCF 2.64
P/OCF 2.64
P/B 2.52
P/tB 5.66
EV/EBITDA 7.38
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.06
FCFY37.85%
OCF(TTM)0.06
OCFY37.95%
SpS0.22
BVpS0.06
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.47%
ROE -58.41%
ROCE 12.19%
ROIC 8.78%
ROICexc N/A
ROICexgc N/A
OM 3.3%
PM (TTM) N/A
GM 37.1%
FCFM 25.54%
ROA(3y)-15.3%
ROA(5y)-19%
ROE(3y)-22.22%
ROE(5y)-31.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-5.88%
F-Score6
Asset Turnover1.43
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.02
Debt/EBITDA 0.05
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 493.88%
Profit Quality N/A
Current Ratio 1.12
Quick Ratio 1.12
Altman-Z 0.83
F-Score6
WACC8.47%
ROIC/WACC1.04
Cap/Depr(3y)3.28%
Cap/Depr(5y)2.81%
Cap/Sales(3y)1.16%
Cap/Sales(5y)1.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-60.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1146.15%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)237.82%
Revenue growth 3Y135.68%
Revenue growth 5Y26.59%
Sales Q2Q%43.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y137.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y296.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y297.04%
OCF growth 3YN/A
OCF growth 5YN/A